Supplementary Issue: Inflammation, Atherosclerosis and Coronary Artery Disease

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases

Masato Furuhashi¹, Shigeuki Saitoh², Kazuaki Shimamoto³ and Tetsuji Miura¹

¹Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
²Department of Nursing, Division of Medical and Behavioral Subjects, Sapporo Medical University School of Health Sciences, Sapporo, Japan. ³Sapporo Medical University, Sapporo, Japan.

ABSTRACT: Over the past decade, evidences of an integration of metabolic and inflammatory pathways, referred to as metaflammation in several aspects of metabolic disease, have been accumulating. Fatty acid-binding protein 4 (FABP4), also known as adipocyte FABP (A-FABP) or aP2, is mainly expressed in adipocytes and macrophages and plays an important role in the development of insulin resistance and atherosclerosis in relation to metaflammation. Despite lack of a typical secretory signal peptide, FABP4 has been shown to be released from adipocytes in a non-classical pathway associated with lipolysis, possibly acting as an adipokine. Elevation of circulating FABP4 levels is associated with obesity, insulin resistance, diabetes mellitus, hypertension, cardiac dysfunction, atherosclerosis, and cardiovascular events. Furthermore, ectopic expression and function of FABP4 in several types of cells and tissues have been recently demonstrated. Here, we discuss both the significant role of FABP4 in pathophysiological insights and its usefulness as a biomarker of metabolic and cardiovascular diseases.

KEYWORDS: fatty acid-binding protein, metabolic syndrome, inflammation, cardiovascular disease

SUPPLEMENT: Inflammation, Atherosclerosis and Coronary Artery Disease

CITATION: Furuhashi et al. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. Clinical Medicine Insights: Cardiology 2014:8(S3):23–33 doi: 10.4137/CMC.S1706 7.

RECEIVED: October 22, 2014. RESUBMITTED: December 16, 2014. ACCEPTED FOR PUBLICATION: December 16, 2014.

ACADEMIC EDITOR: Thomas E. Vanhecke, Editor in Chief

TYPE: Review

FUNDING: In relation to this review article, Masato Furuhashi has been supported by grants from JSPS KAKENHI, Uehara Memorial Foundation, SENSISHIN Medical Research Foundation, Japan Diabetes Foundation, Takeda Medical Research Foundation, Ono Medical Research Foundation, Takeda Science Foundation, Akiyama Life Science Foundation, Yamaguchi Endocrine Research Foundation, and Kondo Kinen Medical Foundation. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

COMPETING INTERESTS: Authors disclose no potential conflicts of interest.

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

CORRESPONDENCE: furuhashi@sapmed.ac.jp

Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Introduction

It has recently been reported that metabolically driven low-grade and chronic inflammation is observed in various types of metabolic disorders, including obesity, insulin resistance, type 2 diabetes, and cardiovascular disease.¹,² The atypical inflammation emerging from metabolic tissues is referred to as metaflammation. Metaflammation is triggered by a surplus of nutrients and metabolites that engage a group of molecules with signaling pathways involved in canonical inflammation. Such signal pathways are mediated by c-Jun N-terminal kinase (JNK), inhibitor of nuclear kappa B kinase (IKK), double-stranded RNA-dependent protein kinase (PKR), and others,¹,² and are responsible for the inhibition of insulin signaling and a vicious cycle of further production of inflammatory mediators through transcriptional regulation by activating protein-1 (AP-1) and nuclear factor-kappa B (NF-κB).³–⁵

In this article, we focus on fatty acid-binding proteins (FABPs) derived from metabolically active cells, especially FABP4, and discuss both the significant role of FABP4 in pathophysiological insights and its usefulness as a biomarker in the context of metabolic and cardiovascular diseases.
Fatty Acid-Binding Proteins

FABPs are a family of 14–15-kDa proteins, known as intracellular lipid chaperones, that regulate lipid trafficking and responses in cells.6,7 FABPs can reversibly bind to hydrophobic ligands, such as saturated and unsaturated long-chain fatty acids (FAs), eicosanoids, and other lipids, with high affinity and broad selectivity.6,9 FABPs are found in all species, from Caenorhabditis elegans and Drosophila melanogaster to rodents and humans, demonstrating strong evolutionary conservation.10–12 Since the first report of FABPs in 1972,12 at least nine different isoforms have been identified in mammals to date. Different isoforms of the FABP family are uniquely expressed in tissues involved in active lipid metabolism. In general, the amount of FABP in cells is proportional to the rates of FA metabolism.14 The family consists of liver (L-FABP/FABP1), intestinal (I-FABP/FABP2), heart (H-FABP/FABP3), adipocyte (A-FABP/FABP4/p2), epididymal (E-FABP/FABP5/mall), ileal (II-FABP/FABP6), brain (B-FABP/FABP7), myelin (M-FABP/FABP8), and testis (T-FABP/FABP9) isoforms.

FABPs exhibit about 15–70% sequence identity between different isoforms.31 However, FABPs share almost similar three-dimensional structures, showing two orthogonal five-stranded β-sheets by a 10-stranded anti-parallel β-barrel structure.6,11 The FA-binding pocket is located inside the β-barrel, and usually, one long-chain FA can be bound to the interior cavity of FABPs except for FABP1. There are differences between the different isoforms in binding affinity and ligand selectivity because of structural differences.11 In general, hydrophobic ligand has a tight binding affinity for FABPs, except for unsaturated FAs.

FABPs have been proposed to actively facilitate the transport of FAs to specific organelles in the cell for lipid oxidation in the mitochondrion or peroxisome; lipid-mediated transcriptional regulation in the nucleus; signaling, trafficking, and membrane synthesis in the endoplasmic reticulum (ER); and regulation of enzyme activity and storage as lipid droplets in the cytoplasm.6 FABPs are also involved in the conversion of FAs to eicosanoids and the stabilization of leukotriene.15,16

FABPs in Adipocytes: FABP4 and FABP5

FABP4, also known as adipocyte FABP (A-FABP), was first detected in adipose tissue and mature adipocytes.37,18 This protein has also been termed adipocyte P2 (αP2) since there is high sequence similarity (67%) with the myelin P2 protein (M-FABP/FABP8).18 FABP4 is highly expressed in adipocytes and consists of about 1% of all soluble proteins in adipose tissue.19 Expression of FABP4 is highly induced during adipocyte differentiation and transcriptionally controlled by peroxisome proliferator-activated receptor (PPAR) γ agonists, FAs, dexamethasone, and insulin.20–24

FABP4-deficient mice showed an increase in body weight but reduced insulin resistance in both high-fat diet-induced and genetic obesity mouse models, but the effect of FABP4 on insulin sensitivity was not observed in lean mice (Fig. 1).25,26 It has been postulated that FABP4 activates hormone-sensitive lipase (HSL) in adipocytes, regulating lipolysis.27,28 In fact, FABP4-deficient adipocytes exhibited reduced efficiency of lipolysis.29,30 Knockdown of FABP4 gene by RNA interference in dietary obese mice increased body weight and fat mass without significant changes in glucose and lipid homeostasis.31 The phenotypic feature of FABP4-deficient mice is similar to the phenotype of FABP4 heterozygous knockout mice on a high-fat diet,32 indicating that remaining FABP4 protein sustains some elements of FABP4 function in control mice. The loss of FABP4 in adipocytes is compensated by FABP5, an FABP known as E-FABP or mall.25

FABP5 is most abundantly present in epidermal cells of the skin but is also expressed in several other cells and tissues including adipocytes.6 The amount of FABP5 is about 100-fold lower than that of FABP4 in adipocytes.33 FABP4 and FABP5 have 52% amino acid similarity and bind to several FAs with similar affinity and selectivity.10

In transgenic mice in which FABP5 was overexpressed in adipose tissue, basal lipolysis and hormone-stimulated lipolysis were enhanced, and insulin sensitivity was reduced in mice on a high-fat diet.33,34 FABP5 deficiency mildly increased systemic insulin sensitivity in dietary and genetic obesity mouse models.33 FABP5-deficient adipocytes demonstrated an increased capacity for insulin-stimulated glucose transport. Except for increased FABP3 (H-FABP) in the liver,35 there was no compensatory increase in the expression of FABPs in tissues of FABP5-deficient mice.31

FABPs in Macrophages: FABP4 and FABP5

Both FABP4 and FABP5 are also expressed in macrophages and dendritic cells.36,37 though the amount of FABP4 in adipocytes is about 10,000-fold higher than that in macrophages.38 Under physiological conditions, the stoichiometry of FABP4 and FABP5 appears to be nearly equal in macrophages.36 Unlike in adipocytes, FABP5 did not appear to be significantly upregulated in FABP4-deficient macrophages.36 The mechanism underlying compensatory changes in FABPs is unknown.

Expression of FABP4 is induced during differentiation from monocytes to macrophages and by treatment with lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate, PPARγ agonists, oxidized low-density lipoprotein, and advanced glycation end products.36,39–41 Conversely, atorvastatin, a cholesterol-lowering drug, has been shown to reduce FABP4 expression in macrophages.44 Metformin, an antidiabetic drug, has also been reported to inhibit forkhead box protein O1 (FOXO1)-mediated transcription of FABP4 and reduce lipid accumulation in macrophages.45

In macrophages, FABP4 increases accumulation of cholesterol ester and foam cell formation via inhibition of the PPARγ-liver X receptor α (LXRα)-ATP-binding cassette A1 (ABCA1) pathway and induces inflammatory responses through activation of the IKK-NF-κB and JNK-AP-1.
FABP4 in metabolic and cardiovascular diseases

Ablation of FABP4 protected against atherosclerosis in apolipoprotein E (ApoE)-deficient mice with or without high-cholesterol western-style diets (Fig. 1). Bone marrow transplantation studies demonstrated that actions in macrophages are predominant for the protective effect of FABP4 deficiency on atherosclerosis rather than actions in adipocytes. FABP4 in dendritic cells has been shown to regulate the IKK-NF-κB pathway and T-cell priming, which might contribute to the development of atherosclerosis since both dendritic cells and T-cells are involved in the pathogenesis of atherosclerosis. As evidence of atherosclerosis in humans, expression of FABP4 in macrophages has been shown to be increased in unstable carotid plaques of human endarterectomy samples.

Expression of FABP5 in macrophages is increased by treatment with toll-like receptor (TLR) agonists: LPS, a TLR4 agonist, and zymosan, a fungal product that activates TLR2. In addition to FABP4, FABP5 may also play a role in atherosclerosis via TLRs and/or other mechanisms. Ablation of FABP5 suppressed atherosclerosis in LDL receptor-deficient mice on a western-style hypercholesterolemic diet, and the anti-atherosclerotic effect of FABP5 deletion was associated with reduction of the expression of inflammatory genes, interleukin 6 and cyclooxygenase-2, and suppression of macrophage recruitment in atherosclerotic lesions because of decreased expression of CC chemokine receptor 2.

Combined Deficiency of FABP4 and FABP5
As described above, both FABP4 and FABP5 in adipocytes and macrophages play important roles in the development of insulin resistance and atherosclerosis (Fig. 1). Mice with combined deficiency of FABP4 and FABP5 (Fabp4−/− Fabp5−/−) on dietary and genetic obesity models exhibited improvement in insulin resistance and protection against type 2 diabetes and fatty liver disease more than did FABP4- or FABP5-deficient mice. Macrophage infiltration and accumulation in adipose tissue has been suggested to be an important feature of obesity-triggered metaflammation. Although the effect of FABP4 or FABP5 on atherosclerosis was mainly due to their actions in macrophages, bone marrow transplantation and cell-based co-culture experiments with adipocytes and macrophages using wild-type and Fabp4−/−Fabp5−/− mice showed that FABP actions in adipocytes and those in macrophages have distinct roles in regulation of insulin sensitivity through metabolic and inflammatory responses. Furthermore, Fabp4−/−Fabp5−/− mice intercrossed into an ApoE-deficient atherosclerosis model showed dramatically suppressed development of atherosclerosis compared to that in FABP4-deficient or wild-type mice on the same background. Interestingly, Fabp4−/−Fabp5−/−ApoE−/− mice on a hypercholesterolemic diet also had a significantly higher survival rate than that of ApoE−/− mice, probably due to better plaque stability and metabolic health.

Figure 1. Association of FABP4 in adipocytes and macrophages with metabolic and cardiovascular diseases. FABP4 acts at the interface of metabolic and inflammatory pathways in adipocytes and macrophages and plays important roles in the development of insulin resistance, diabetes mellitus, and atherosclerosis. Chemical inhibition of FABP4 could be a therapeutic strategy against metabolic and cardiovascular diseases. BMS309403, one of the specific FABP4 inhibitors, is an orally active small molecule and interacts with the fatty acid-binding pocket within the interior of FABP4 to inhibit binding of endogenous fatty acid (FA). Intracellular FA-bound FABP4 (PDB code: 2hnx). Inhibitor-bound FABP4 (PDB code: 2nnq).
Lipidomic analyses using samples from different tissues, including adipose tissue, skeletal muscle, liver, and blood in FABP4-/-FABP5-/- and wild-type mice, showed significantly increased de novo lipogenesis by induction of stearoyl-CoA desaturase-1 (SCD-1) and FA synthase in adipose tissue. As a result, palmitoleate (C16:1n7), an unsaturated free FA, was identified as an adipose tissue-derived lipid hormone, referred to as lipokine, that decreases fatty liver and increases glucose uptake in skeletal muscle. Deletion of FABP4 in macrophages also increased de novo lipogenesis pathways through LXRα-mediated SCD-1 activation, resulting in production of palmitoleate and resistance to ER stress. Conversely, unsaturated FAs, including palmitoleate, modulated histone deacetylation, resulting in decreased basal and LPS-induced expression of FABP4 in macrophages.

A role of a lipokine in human pathophysiology has been suggested by recent clinical studies. In a study in which 100 Caucasian subjects were recruited, palmitoleate level was positively correlated with insulin sensitivity assessed by euglycemic-hyperinsulinemic clamp studies, independent of age, gender, and adiposity. Another study in which 3630 subjects in the US were enrolled showed that high level of cis isomer palmitoleate, which is primarily produced by the liver in humans, was associated with adiposity and consumption of alcohol and carbohydrate. Interestingly, it has recently been reported that the level of trans isomer of palmitoleate, an exogenous source of C16:1n7, is associated with lower insulin resistance, lower incidence of diabetes, and higher HDL-cholesterol level, suggesting a potential strategy for intervention by metabolic benefits of dairy product consumption in human diseases.

**Potential Functional Domains of FABP4**

A nuclear localization signal (NLS) and a nuclear export signal (NES) have been reported in potential functional domains of FABP4. The primary sequence of FABP4 does not reveal a typical NLS or NES. However, the signals could be found in the three-dimensional structure of FABP4 and were mapped to three basic residues (K21, R30, and K31) for NLS and three nonadjacent leucine residues (L66, L86, and L91) for NES. The NLS in FABP4 is activated by closure of the portal loop and perturbation of a swinging doorway comprised F57. Non-activating ligands, such as oleate and stearate, protrude from the portal and prevent its closure, leading to the masking of the NLS, while activating ligands, such as linoleic acid, troglitazone, and anilinonaphthalene sulfonate, expose the NLS.

As a small intracellular protein, FABP4 may access the nucleus and target FAs to transcription factors, such as members of the PPAR family, in the nuclear lumen. It has been reported that FABP4 expression itself is controlled by PPARγ. A recent study has indicated that continuous shuttling between the nucleus and cytoplasm is involved in transcriptional activation of PPARγ by FABP4. However, it has also been shown that FABP4 has inhibitory action of PPARγ in macrophages.

Another domain of FABP4 includes an HSL binding site. A direct protein–protein interaction between FABP4 and HSL activity in adipocytes has been reported to regulate lipolysis. Adipocytes in FABP4-deficient mice have reduced lipolysis in vitro and in vivo. Interestingly, during experimentally induced lipolysis, FABP4-deficient mice showed reduction in insulin secretion.

FABP4 has been reported to decrease Janus kinase 2 (JAK2) signaling via protein–protein interaction, indicating a novel role of FABP4 as a FA sensor affecting metabolism in the cell. Phosphatase and tensin homolog on chromosome 10 (PTEN), which negatively regulates the phosphoinositide 3-kinase pathway, has also been reported to interact with FABP4, possibly regulating adipocyte differentiation and lipid metabolism. Interestingly, PTEN-deficient keratinocytes increased expression of FABP4, suggesting that PTEN transcriptionally regulates FABP4 expression.

**Secretion of FABP4 as an Adipokine**

FABP4 lacks an N-terminal secretory signal sequence, which is necessary for the classical secretory pathway, ie, ER–Golgi-dependent pathway. However, proteins can also be actively secreted from eukaryotic cells via ER–Golgi-independent pathways. Previous studies demonstrated that FABP4 secretion was not modulated by treatment with brefeldin A and monensin, inhibitors of protein secretion by blocking vesicular traffic at the ER and the Golgi apparatus, indicating a non-classical secretion mechanism for FABP4.

In adipocytes, there are two distinct signal pathways of activation of lipolysis by phosphorylation of HSL: β-adrenergic receptor-mediated adenyl cyclase (AC)-protein kinase A (PKA) and natriuretic peptide receptor-A (NPR-A)-mediated guanylyl cyclase (GC)-protein kinase G (PKG) pathways. We recently showed that FABP4 is secreted from adipocytes in association with lipolysis through both AC-PKA and GC-PKG pathways (Fig. 2). Since it has been reported that lipolysis is mediated in part through the interaction of FABP4 with HSL in adipocytes, there is a dual regulatory mechanism of FABP4 secretion in adipocytes. FABP4 may also be a carrier protein for transport of FAs generated by lipolysis from lipid droplets to extracellular and/or intracellular utilization. In humans, plasma FABP4 level significantly declined after an oral glucose tolerance test or after eating a high-fat meal, while the insulin level increased. Suppression of FABP4 secretion by insulin-induced anti-lipolytic signaling may be involved in this decline in FABP4 level.

FABP4 secretion from human adipocytes has also been shown to be increased by ionomycin, an ionophore that raises intracellular Ca2+ levels, indicating contribution of a calcium-dependent secretory mechanism. In addition, FABP4 is secreted partially by microvesicles derived from adipocytes (an established mechanism for unconventional secretion).
FABP4 in metabolic and cardiovascular diseases

Figure 2. Secretion of FABP4 in association with lipolysis. FABP4 lacks an N-terminal secretory signal sequence, which is necessary for the classical ER–Golgi-dependent secretory pathway, but FABP4 can be secreted via the ER–Golgi-independent pathway. FABP4 is secreted from adipocytes in association with two distinct signal pathways of activation of lipolysis by phosphorylation of HSL, including β-adrenergic receptor-mediated AC-PKA and NPR-A-mediated GC-PKG pathways. FABP4 also interacts with HSL for regulation of its activity. FABP4 may be a carrier protein for transport of FAs generated by lipolysis from lipid droplets to extracellular and/or intracellular utilization.

Abbreviations: AC, adenyl cyclase; AR, adrenergic receptor; ATGL, adipose triglyceride lipase; AQP7, aquaporin 7; DAG, diacylglyceride; ER, endoplasmic reticulum; FA, fatty acid; GC, guanylyl cyclase; HSL, hormone-sensitive lipase; MAG, monoacylglyceride; MGL, monoacylglycerol lipase; NPR-A, natriuretic peptide receptor-A; TAG, triacylglyceride; IRS-1, insulin receptor substrate 1; PDE-3B, phosphodiesterase 3B; PI3K, phosphatidylinositol-3-kinase; PKA, protein kinase A; PKB, protein kinase B; PKG, protein kinase G.

from adipocytes, and both microvesicle-free-mediated and microvesicle-secreted FABP4 are downregulated by insulin and upregulated by ionomycin. However, the release of FABP4 via adipocyte-derived microvesicles is a small fraction and conveys a minor activity. Taken together, the findings indicate that FABP4 is actively released by unconventional mechanisms and by adipocyte-derived microvesicles from adipocytes through AC-PKA- and GC-PKG-dependent signal pathways and/or an intracellular calcium-dependent mechanism.

Proteomic analysis showed the presence of FABP4 in cell supernatants derived from differentiated THP-1 macrophages, suggesting that FABP4 is also secreted from macrophages. In bone marrow transplantation using wild-type and FABP4/5-deficient mice, bone marrow-derived cells from wild-type mice could not sustain a detectable level of plasma FABP4 in FABP4/5-deficient mice, indicating that the predominant contributors of circulating FABP4 are adipocytes rather than macrophages. The biological roles of extracellular FABP4 derived from macrophages remain unknown, but there might be local effects of macrophage-derived FABP4 on metaflammation.

Evidences supporting extracellular roles of FABP4 as an adipokine are accumulating with great importance. The secreted form of FABP4 may be biologically active, leading to a paradigm shift in the understanding of FABPs as lipid chaperones and the local networking of metabolic and inflammatory responses (Fig. 3). Direct effects of exogenous FABP4 have been demonstrated in multiple types of cells; FABP4 enhanced hepatic glucose production in vivo and in vitro, decreased cardiomyocyte contraction in vitro, inhibited expression/activation of endothelial nitric oxide synthase (eNOS) in vascular endothelial cells, and increased proliferation/migration of vascular smooth muscle cells and glucose-stimulated insulin secretion in pancreatic β cells. Future investigation should provide further insights into extracellular roles of FABP4 and how they contribute to progression of diseases.

Circulating Concentration of FABP4 as a Potent Biomarker

Recent studies have shown the presence of FABPs in human circulation. Since FABPs lack a secretory signal sequence, the detection of FABPs in circulation is thought to be a biochemical marker of tissue injury in related cells: FABP1 (L-FABP) for liver injury, FABP2 (I-FABP) for intestinal damage, FABP3 (H-FABP) for ongoing myocardial damage in acute myocardial infarction or heart failure, and FABP7 (B-FABP) for brain injury. On the other hand, it has been shown that FABP4 is secreted from adipocytes and may act as an adipokine as...
Furuhashi et al described above. FABP4 concentration was the highest among levels of FABP1–5 under a physiological condition in a general population without pharmacological treatments. FABP4 level is significantly higher in females than in males, possibly because of the larger amount of body fat in females than in males since there is an independent and strong correlation between FABP4 level and adiposity. Consistent with the results of previous studies showing that levels of several FABPs were increased in subjects with renal dysfunction, serum FABP4 level was shown to be negatively correlated with estimated glomerular filtration rate in recent studies, suggesting that FABPs are eliminated from the circulation mainly by renal clearance. We previously showed that FABP4 level in hemodialysis patients with end-stage kidney disease was about 20 times higher than that in controls with normal renal function and was decreased by 57.2% after hemodialysis.

It has been reported that increased circulating FABP4 levels are associated with obesity, insulin resistance, type 2 diabetes, hypertension, cardiac dysfunction, and atherosclerosis. Circulating FABP4 level was significantly increased in obese subjects compared to the level in lean controls, and serum FABP4 level was positively correlated with waist circumference, blood pressure, and insulin resistance. High concentration of FABP4 at baseline was an independent predictor for the development of metabolic syndrome during a five-year follow-up period in a Chinese population.

A 10-year prospective study also showed that high level of FABP4 at baseline independently predicted the development of type 2 diabetes. We previously demonstrated significant elevation of circulating FABP4 level in patients with essential hypertension and insulin resistance, correlation of FABP4 concentration with indices of insulin resistance, and association of elevation of FABP4 level with family history of hypertension, suggesting a role of FABP4 in genetic predispositions for the development of essential hypertension. Associations of FABP4 levels with the development of left ventricular (LV) hypertrophy and with systolic and diastolic cardiac dysfunction have also been reported. Our recent study demonstrated that FABP4 level was associated with LV diastolic dysfunction even in an apparently healthy population with no medication. It has also been reported that serum FABP4 level is associated with atherosclerosis assessed by carotid intima-media thickness. These findings support the notion that circulating FABP4 is not only a potent biomarker but also plays an important role, as an adipokine, in the development of metabolic syndrome and cardiovascular diseases (Fig. 3).

A genetic variant at the FABP4 locus associated with decreased FABP4 expression in adipose tissue has been suggested to reduce the risk of cardiovascular diseases in a population study. We and others previously showed that serum FABP4 level predicts long-term cardiovascular events. Furthermore, a large-scale prospective study showed that concentration of FABP4 predicts the risk of heart failure during a median follow-up of 10.7 years. Accumulating evidences of a causative role of FABP4 in cardiovascular events, including atherosclerosis and cardiac dysfunction, indicate that FABP4 is potentially a novel target for prevention of cardiovascular diseases (Fig. 3). Other than cardiovascular pathologic processes, FABP4 level has been shown to be a

---

**Figure 3.** Possible action of circulating FABP4. FABP4 is secreted from adipocytes in association with lipolysis and may contribute to the development of insulin resistance, diabetes mellitus, atherosclerosis, hypertension, and cardiac dysfunction, leading to poor prognosis by cardiovascular death. Metabolic and cardiovascular disease-mediated activation of the sympathetic nerve system and/or induction of inflammatory cytokines may increase lipolysis in adipocytes, resulting in a vicious spiral of additional production of secreted FABP4. Inhibition or neutralization of secreted FABP4 may represent an effective therapeutic strategy against metabolic and cardiovascular diseases.
novel prognostic factor in patients with breast cancer independent of obesity.\textsuperscript{109} It has been reported that several drugs modify circulating FABP4 levels. Atorvastatin, a HMG-CoA reductase inhibitor, and several angiotensin II receptor blockers reduced FABP4 concentrations.\textsuperscript{110–112} On the other hand, pioglitazone, an insulin-sensitizing thiazolidinedione (a PPAR\(\gamma\) agonist), increased FABP4 levels,\textsuperscript{113} presumably because of direct activation of PPAR\(\gamma\) since the \(\text{Fabp4}\) gene promoter includes the PPAR response element.\textsuperscript{114} Of note, similar to FABP4, circulating FABP5 has been reported to be detected at levels of about 1/10th or less of FABP4 concentrations, and FABP5 levels were associated with components of metabolic syndrome, although the correlation was not as strong as that of FABP4.\textsuperscript{89,115,116} Contribution of FABP5 to metabolic syndrome and cardiovascular diseases remains to be elucidated.

**Ectopic FABP4 Expression**

There are accumulating evidences indicating FABP4 is expressed in several types of cells, in addition to adipocytes and macrophages, under both physiological and pathological conditions (Fig. 4). For example, expression of FABP4 was observed in endothelial cells of capillaries and small veins in the heart and kidney.\textsuperscript{117} As a physiological function, FABP4 in capillary endothelial cells of the heart and skeletal muscle interstitial capillaries is involved in transendothelial FA transport into FA-consuming organs.\textsuperscript{118} Treatment of endothelial cells with vascular endothelial growth factor-A (VEGF-A) via VEGF-receptor-2 (VEGFR2) or basic fibroblast growth factor (bFGF) induced FABP4 expression.\textsuperscript{117} FABP4 in endothelial cells has also been reported to promote angiogenesis.\textsuperscript{119–121} Interestingly, roles of FABP4 in vascular injury have been reported. FABP4 was markedly induced in regenerated endothelial cells after endothelial balloon denudation \textit{in vivo}.\textsuperscript{122} Intermittent hypoxia also increased expression of FABP4 in human aortic endothelial cells.\textsuperscript{123} Conversely, angiopoietin-1 inhibited FOXO1-mediated FABP4 expression in endothelial cells.\textsuperscript{124} FABP4 was expressed in the aortic endothelium of 12-week old, but not 8-week old, ApoE-deficient mice showing endothelial dysfunction.\textsuperscript{125} Chronic treatment with BMS309403, a small molecule FABP4 inhibitor, significantly improved endothelial dysfunction in ApoE-deficient mice.\textsuperscript{126} Notably, it has recently been shown the possible involvement of FABP4 and FABP5 in senescence of endothelial cells.\textsuperscript{126,127} These observations support the notion that ectopic expression of FABP4 under pathological condition, but not physiological FABP4 expression, in the endothelium contributes to the pathogenesis of atherosclerosis and vascular injury.

In normal kidneys, FABP4 is expressed in endothelial cells of the tubulointerstitial peritubular capillary and vein in both the cortex and medulla, but not in glomerular or arterial endothelial cells, under normal physiological condition.\textsuperscript{117} We recently demonstrated that ectopic expression of FABP4 in the glomerulus is associated with progression of proteinuria and renal dysfunction.\textsuperscript{128} Among FABPs, FABP1 (L-FABP) is expressed in proximal tubular epithelial cells in the kidney, and urinary FABP1 has been reported to reflect damage of proximal tubular epithelial cells.\textsuperscript{129,130} Our recent study\textsuperscript{131}
suggests that urinary FABP4 is a novel biomarker reflecting glomerular damage and that determination of both FABP1 and FABP4 in urine enables better characterization of renal injury.

Evidences for the involvement of FABP4 in respiratory diseases have also been accumulating. FABP4 was detected in endothelial cells of peribronchial blood vessels and a subset of macrophages in lungs and bronchoalveolar samples from patients with bronchopulmonary dysplasia (BPD). Several studies using lung lavage cells suggested that expression of FABP4 is involved in pathogenesis of sarcoidosis. Furthermore, the Th2 cytokines IL-4 and IL-13, which are involved in the development of asthma, increased FABP4 expression in bronchial epithelial cells, and the Th1 cytokine interferon γ suppressed expression of FABP4. Interestingly, FABP4-deficient mice showed protection against asthma and airway inflammation through FABP4 action in stromal cells but not bone marrow-derived cells.

It has been reported that FABPs, including FABP4, are expressed in human placental trophoblasts and that FABP4 is a key regulator of trophoblastic lipid transport and accumulation during placentation. FABP4 was detected in apoptotic granulosa cells in atretic antral follicles of the mouse ovary, suggesting a possible relevance to polycystic ovary syndrome (PCOS), which is known to frequently coexist with insulin resistance. Expression of Fabp4 mRNA in isolated granulosa cells was higher in patients with PCOS than in controls. Association of FABP4 gene polymorphisms with the development of PCOS has also been reported.

Roles of FABP4 in modifications of tumor cell growth and apoptosis have been suggested by several studies. In ovarian cancer metastasis, FABP4 was detected in human ovarian cancer cells at the adipocyte–tumor cell interface, and FABP4 deficiency in mice substantially impaired metastatic tumor growth. FABP4 expression was also detected in lipoblasts of lipoblastoma and liposarcoma. Moreover, expression of FABP4 has been linked to glioblastoma and urothelial carcinomas. Additionally, treatment of mouse spleen and cultured T lymphocytes with dexamethasone induced FABP4 expression and its nuclear localization in association with apoptosis process.

**FABP4 as a Therapeutic Target**

The expression, regulation, and metabolic function of intracellular and extracellular human FABP4 have been reported to be similar to those of mouse FABP4. In fact, individuals with T-87C, a genetic variant of the human FABP4 gene within the promoter region, were protected from obesity-induced type 2 diabetes and exhibited diminished FABP4 expression in adipose tissue, lower triglyceride levels, and reduced cardiovascular disease risk. These findings provide a critical proof-of-principle that the biological functions of FABP4 are similar in mice and humans. Since FABP4 acts at the interface of metabolic and inflammatory pathways and plays a significant role in the development of obesity, insulin resistance, type 2 diabetes, and atherosclerosis as described above, it is expected that agents capable of modifying FABP4 function would become a new class of therapeutic agents with multi-indications. To date, several series of FABP4 inhibitors have been synthesized. We previously demonstrated the effect of BMS309403, a specific FABP4 inhibitor, on insulin resistance, diabetes mellitus, fatty liver disease, and atherosclerosis in experimental models, indicating that chemical inhibition of FABP4 could be a therapeutic strategy against several aspects of metabolic syndrome. BMS309403 is an orally active small molecule and interacts with the FA-binding pocket within the interior of FABP4 to inhibit binding of endogenous FAs (Fig. 1). In addition, a recent study showed that neutralization of secreted FABP4 by neutralizing antibodies reduced hepatic glucose production and corrected the diabetic phenotype of obese mice. Neutralizing or eliminating secreted FABP4 may also represent an effective therapeutic strategy against metabolic and cardiovascular diseases (Fig. 3). Further studies are obviously needed to investigate whether chemical or other types of inhibition and neutralization of FABP4 can be safely used in humans and to show the efficacy of agents for metabolic and cardiovascular diseases.

**Concluding Remarks**

FABP4 is involved in the regulation of glucose and lipid metabolism in relation to inflammatory and metabolic processes in target cells, especially adipocytes and macrophages. Under normal physiologic conditions, FABP4-deficient mice have no compromised phenotype. However, FABP4-deficient mice on dietary or genetic obesity were protected from systemic pathologic stresses such as inflammation, suggesting that the FABP4 gene would be one of the thrifty genes. FABPs have been evolutionarily preserved from invertebrates (lower eukaryotes) to vertebrates including humans, indicating a close link between inflammatory and metabolic responses by the conserved function of FABP. The presence of FABP4 in cells may have been beneficial for storing energy in adipose tissue or for acting as a strong immune response in macrophages against pathogens. In addition, secreted FABP4 in association with lipolysis during fasting may regulate hepatic glucose production as the thrifty phenotype to survive in famine. Under contemporary lifestyle with excessive caloric intake and decreased energy expenditure, the presence, induction, or enhanced secretion of FABP4 may be rather disadvantageous for regulating inflammatory or metabolic homeostasis. In recent metabolic disorders, as an evolutionary bottleneck in humans, inhibition or neutralization of FABP4 could be a promising novel class of therapeutics against several metabolic and cardiovascular diseases, and possibly other diseases such as asthma and cancer metastasis as well.
Acknowledgments
The authors are grateful to group members of their department for their scientific contribution. They also regret the inadvertent omission of many important references because of space limitations.

Author Contributions
Wrote the first draft of the manuscript: MF. Contributed to the writing of the manuscript: MF, SS, KS, TM. Agree with manuscript results and conclusions: MF, SS, KS, TM. Jointly developed the structure and arguments for the paper: MF, SS, KS, TM. Made critical revisions and approved final version: MF, SS, KS, TM. All authors reviewed and approved of the final manuscript.

REFERENCES
1. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121): 860–7.
2. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Ann Rev Immunol. 2011;29:415–45.
3. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333–6.
4. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikbeta. Science. 2001;290(5535):1673–7.
5. Nakamura T, Furushashi M, Li P, et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell. 2010;140(3):38–48.
6. Furushashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7(8):650–5.
7. Furushashi M, Ishimura S, Ota H, Miura T. Lipid chaperones and metabolic inflammation. Int J Inflam. 2011;2011:642612.
8. Coe NR, Bernlohr DA. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta. 1998;1391(3):287–306.
9. Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci. 2002;59(7):1096–116.
10. Haunerland NH, Spencer F. Fatty acid-binding proteins – insights from genetic manipulations. Prog Lipid Res. 2004;43(4):328–49.
11. Chumarynska A. The multigene family of fatty-acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 2006;47(1):39–48.
12. Estrees A, Ehrlieh R. Invertebrate intracellular fatty acid binding proteins. Comp Biochem Physiol C Toxicol Pharmacol. 2006;142(4–5):262–74.
13. Ockner RK, Manning JA, Poppenhausen RB, Ho WK. A binding protein for fatty acids in cecum of intestinal mucosa, liver, myocardium, and other tissues. Science. 1972;177(4043):56–8.
14. Veerkamp JH, van Moerkerk HT. Fatty acid-binding protein and its relation to development and homology of 5′-flanking sequences among fat cell-specific genes. J Biol Chem. 1992;267(9):5937–41.
Furuhashi et al.

47. Hui X, Li H, Zhou Z, et al. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem. 2010;285(14):10273–80.

48. Boord JB, Maeda K, Makowski L, et al. Adipocyte fatty acid-binding protein, apoA II, alters atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002;22(10):1686–91.

49. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204–12.

50. Agarwal HE, Eikeland J, et al. Expression of fatty acid-binding protein apoA2 is correlated with plaque instability in carotid atherosclerosis. J Intern Med. 2011;269(2):200–10.

51. Feingold KR, Kazemi MR, Magra AL, et al. ADRP/ADFP and Mall expression are increased in macrophages treated with TLR agonists. Atherosclerosis. 2009;209(1):81–8.

52. Babaev VR, Runner RP, Fan D, et al. Macrophage Mall deficiency suppresses atherosclerosis in low-density lipoprotein receptor-null mice by activating peroxisome proliferator-activated receptor-gamma-regulated genes. Arterioscler Thromb Vasc Biol. 2011;31(6):1283–90.

53. Maeda K, Cao H, Kono K, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 2005;2(2):107–19.

54. Cao H, Maeda K, Gorgun CZ, et al. Regulation of metabolic responses by adipocyte/macrophage fatty acid-binding proteins in leptin-deficient mice. Diabetes. 2006;55(7):1915–23.

55. Weisberg SP, McCann D, Desai M, Rosenbaum MA, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808.

56. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30.

57. Furuhashi M, Fuchu R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid-binding proteins contribute to macrophage infiltration in both macrophages and adipocytes in mice. J Clin Invest. 2008;118(7):2640–50.

58. Boord JB, Maeda K, Makowski L, et al. Combined adipocyte/macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;109(11):1492–8.

59. Cao H, Grehls RD, Mayers JR, West M, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008;134(6):933–44.

60. Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through injections in both macrophages and adipocytes in mice. J Clin Invest. 2010;120(7):2589–96.

61. Coleman SL, Park YK, Lee JY. Un saturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages. Eur J Nutr. 2011;50(5):323–30.

62. Stefan N, Kastarzinski K, Celebi N, et al. Circulating palmitoleic strongly and independently predicts inflammation in humans. Diabetes Care. 2011;34(2):405–10.

63. Mozaffarian D, Cao H, King IB, et al. Macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;109(11):1492–8.

64. Boord JB, Maeda K, Makowski L, et al. Combined adipocyte/macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;109(11):1492–8.

65. Cao H, Grehls RD, Mayers JR, West M, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008;134(6):933–44.

66. Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through injections in both macrophages and adipocytes in mice. J Clin Invest. 2010;120(7):2589–96.

67. Coleman SL, Park YK, Lee JY. Un saturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages. Eur J Nutr. 2011;50(5):323–30.

68. Stefan N, Kastarzinski K, Celebi N, et al. Circulating palmitoleic strongly and independently predicts inflammation in humans. Diabetes Care. 2011;34(2):405–10.

69. Mozaffarian D, Cao H, King IB, et al. Macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;109(11):1492–8.

70. Cao H, Grehls RD, Mayers JR, West M, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008;134(6):933–44.

71. Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through injections in both macrophages and adipocytes in mice. J Clin Invest. 2010;120(7):2589–96.

72. Coleman SL, Park YK, Lee JY. Un saturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages. Eur J Nutr. 2011;50(5):323–30.
1. Engel S, Utz W, Haufe S, et al. Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women. *Heart*. 2013;99(13):944–8.

2. Huang CL, Wu YW, Wu CC, et al. Association between serum adipocyte fatty-acid-binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. *Cardiovasc Diabetol*. 2013;12:105.

3. Liu M, Zhou M, Bao Y, et al. Circulating adipocyte fatty-acid-binding protein levels are independently associated with heart failure. *Clin Sci*. 2014;126(6):415–21.

4. Baesler A, Lamounier-Zepter V, Penk S, et al. Adipocyte fatty-acid-binding protein levels are associated with left ventricular diastolic dysfunction in morbidly obese subjects. *Nutri Diabet*. 2014;4:e106.

5. Tuncman G, Erbay E, Hom X, et al. A genetic variant at the fatty-acid-binding protein ap2 locus increases the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. *Proc Natl Acad Sci U S A*. 2006;103(18):6970–5.

6. von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbuber D, Brenner H. Circulating adipocyte fatty-acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. *Arterioscler Thromb Vasc Biol*. 2012;32(9):2327–35.

7. Chow WS, Tso AW, Xu A, et al. Elevated circulating adipocyte fatty-acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. *J Am Heart Assoc*. 2012;1(1):e00476.

8. Djoussé L, Bartz TM, Is JH, et al. Fatty acid-binding protein 4 and incident heart failure: the cardiovascular health study. *Eur J Heart Fail*. 2013;15(4):394–9.

9. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. *Breast Cancer Res Treat*. 2010;119(2):367–73.

10. Karpisek M, Stejskal D, Kotolova H, et al. Loss of expression of the adipocytokine adiponectin and synthesis of thiazolidinedione in patients with hyperlipidemia. *Eur J Clin Invest*. 2007;37(8):637–42.

11. Miyoshi T, Doi M, Hirohata S, et al. Olmesartan reduces arterial stiffness and serum adipocyte fatty-acid-binding protein content in hypertensive patients. *Heart*. 2011;97(Suppl 1):109–13.

12. Furushashi M, Mita T, Moniwa N, et al. Angiogenesis inhibitor receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. *Hypertens Res*. 2015;38(5):436–40.

13. Cabeo A, Lázaro I, Girona J, et al. Fatty acid binding protein 4 is increased in metabolic syndrome with thiazolidinedione treatment in diabetic patients. *Atherosclerosis*. 2007;193(1):145–8.

14. Schachtrup C, Emmler T, Bleck B, Sandqvist A, Spener F. Functional analysis of Genes Dev function and gene expression via the transcription factor FKHR (FOXO1). *Biol Chem*. 2000;299(1–2):99–107.

15. Veloski JJ, Fong MW, Wu AH, et al. Urinary fatty acid-binding protein as a screening tool for the endothelial cell-derived putative aging-related protein detected by MS/MS. *Proteomics*. 2006;6(13):3339–51.

16. Lee MY, Wang Y, Vanhoutte PM. Senescence of cultured porcine coronary arterial endothelial cells is associated with accelerated oxidative stress and activation of NFκB. *J Vas Res*. 2010;47(4):287–98.

17. Tanaka M, Furuhashi M, Okazaki Y, et al. Expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction. *Nephrol Dial Transplant*. 2015;30(1):95–102.

18. Kajimura A, Kimura M, Sugaya T, et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. *J Lab Clin Med*. 2013;162(4):23–30.

19. Ntiri E, Doi K, Negishi K, et al. Urinary fatty acid-binding protein I: an early predictive biomarker of kidney injury. *Am J Physiol Renal Physiol*. 2009;296(4):F690–79.

20. Okazaki Y, Furuhashi M, Tanaka M, et al. Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction. *PLoS One*. 2014;9(12):e115429.

21. Ghezzi E, Karaslan C, Berkelhammer S, Akar S, Kozakiewich H, Cateni S. Fatty-acid-binding proteins and peribronchial angiogenesis in bronchopulmonary dysplasia. *Am J Respir Cell Mol Biol*. 2011;45(3):550–6.

22. Mave R, Medica J, Petretti C. Search for sarcoidosis candidate genes by integration of data from genomic, transcriptomic and proteomic studies. *Med Sci Monit*. 2007;13(12):SR22–8.

23. Biron-Shental T, Shafrit WF, Ratziczk C, Bildirici I, Nelson DM, Sadowsky Y. Hypoxia regulates the expression of fatty-acid-binding proteins in primary term human amnion cells. *J Matern Fetal Neonatal Med*. 2009;22(4):158–62.

24. Scifres CM, Chen B, Nelson DM, Sadowsky Y. Fatty acid binding protein 4 regulates intracellular lipid accumulation in human trophoblasts. *J Clin Endocrinol Metab*. 2011;96(7):E1803–9.

25. Makkar A, Mishina T, Chang G, Scifres C, et al. Fatty acid binding protein 4 is expressed in the mouse placental labyrinth, yet is dispensable for placental triglyceride accumulation and fetal growth. *Placenta*. 2013;34(10):802–7.

26. Nourani MR, Owada Y, Kitanaka N, et al. Occurrence of immunoreactivity for adipocyte-type fatty acid binding protein in degranulating granulomas in active antral follicles of mouse ovary. *J Mol Histol*. 2005;36(9):491–7.

27. Hu W, Qiao J. Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome. *Endocrine*. 2011;40(2):196–202.

28. Wang J, Tang J, Wang B, et al. FABP4: a novel candidate gene for polycystic ovary syndrome. *Endocrinology*. 2009;150(3):1292–6.

29. Nieman KM, Kenny HA, Pennica CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat Med*. 2011;17(11):1498–503.

30. Bennett JH, Shousha S, Puddle B, Athanasou NA. Immunohistochemical identification of tumour of adipocytic differentiation using an antibody to aP2 protein. *J Clin Pathol*. 1995;48(10):950–4.

31. Cataltepe O, Arikan MC, Ghefl E, et al. Fatty acid binding protein 4 is expressed in distinct endothelial and non-endothelial cell populations in glioblastoma. *Neuropathol Appl Neurobiol*. 2012;38(5):400–10.

32. Ohlsson G, Moreira JM, Gromov P, Sauter G, Celnik JE. Loss of expression of the adipocyte-type fatty-acid-binding protein (A-FABP) is associated with progression of human uterine carcinomas. *Mol Cell Proteomics*. 2005;4(4):570–81.

33. Abdelwahab SA, Owada Y, Kitanaka N, et al. Enhanced expression of adipocyte-type fatty acid binding protein in degranulating granulomas in fibrotic antral follicles of mouse ovary. *J Mol Histol*. 2005;36(9):491–7.

34. Hu W, Qiao J. Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome. *Endocrine*. 2011;40(2):196–202.

35. Wang J, Tang J, Wang B, et al. FABP4: a novel candidate gene for polycystic ovary syndrome. *Endocrinology*. 2009;150(3):1292–6.

36. Nieman KM, Kenny HA, Pennica CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat Med*. 2011;17(11):1498–503.

37. Bennett JH, Shousha S, Puddle B, Athanasou NA. Immunohistochemical identification of tumour of adipocytic differentiation using an antibody to aP2 protein. *J Clin Pathol*. 1995;48(10):950–4.